An interventional study of Implantable cardioverter-defibrillator (ICD) and Optimal Medical Therapy (OMT) in Sudden Cardiac Death and Myocardial Infarction, sponsored by Charite University, Berlin, Germany. Recruiting at 86 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-01.
Sponsored by Charite University, Berlin, Germany · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Death, Sudden, Cardiac with a site in Germany — 6 open to participants now, 7 under way, none of them phase 3. Death, Sudden, Cardiac · Germany.
Among the 43 studies in Death, Sudden, Cardiac with a site in Germany, this one has the largest planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2023, is one of 13 with no phase, and was the 40th registered.
364 studies on the registry are indexed under Death, Sudden, Cardiac; 84 are open to participants now.
Browse Death, Sudden, Cardiac studies →6 of the 43 studies in Death, Sudden, Cardiac with a site in Germany are open now. Recruiting first, the newest first:
Universitätsklinikum Köln · Sites in Germany
University of Luebeck · Sites in Germany
Ages 18–99
Western Sydney Local Health District · Sites in Germany, United States, Australia and 12 more countries
Ages 18–85
Klinik für Kardiologie, Pneumologie und Angiologie · Sites in Germany
Ages 18–80
Universitätsklinikum Köln · Sites in Germany
Ages 8+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 63 Death, Sudden, Cardiac studies recruiting now, 42 (67%) set no upper age limit and 11 (17%) stop at 75 or younger; 22 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 2 started in 2023.
This study's planned enrollment of 3,595 is above the median of 126 across 135 interventional studies indexed under Death, Sudden, Cardiac.
Median enrollment 180 across the 18 interventional studies, 410 across the 24 observational. Of the 27 that completed or were terminated, 4 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 43 have an industry lead sponsor. The 10 most frequent:
Charite University, Berlin, Germany is the lead sponsor of 857 studies on the registry; 128 are open to participants now.
Charite University, Berlin, Germany has 3 studies filed under Death, Sudden, Cardiac — fewer than ten, so there is no comparison to draw.
1 of the studies in Death, Sudden, Cardiac with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05665608Charite University, Berlin, GermanyPrevention Of Sudden Cardiac Death After Myocardial Infarction by Defibrillator Implantation | 2027-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 43 studies in Death, Sudden, Cardiac with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Patients who have survived a myocardial infarction (MI) are at increased risk for sudden cardiac death (SCD) caused by ventricular tachycardia and ventricular fibrillation. A severely reduced left ventricular ejection fraction (LVEF) as a rough overall measure of impaired heart function after MI was shown to indicate a higher risk for SCD. Based on this observation, two landmark randomised trials, MADIT II and SCD-HeFT, were conducted between end of the 1990s and early 2000s. These trials compared the survival of patients with severely reduced LVEF who received an implantable cardioverter-defibrillator with the survival of patients being on medical therapy alone. They reported a significantly better survival of patients in the defibrillator arm and led to international guideline recommendations for routine implantation of defibrillators in survivors of MI with severely impaired LVEF as a means for primary prevention of SCD. Since then, the management of these patients has changed dramatically with the advent of a series of novel drug classes that reduce not only mortality but specifically SCD leading to a substantial decrease of the sudden death rates as well as of the rates of appropriate defibrillator therapies implanted for primary prevention of SCD. At the same time, the complication rates associated with the defibrilllator therapy remain significant without obvious decrease. Thus, the risk-benefit of routine defibrillator implantation for primary prevention of SCD in patients with severely reduced LVEF has substantially changed since the conduction of the landmark trials that established this therapy. Due to the inherent risks and considerable costs of the defibrillator, a novel randomised adequately powered assessment of the potential benefit or harm of the defibrillator in survivors of MI with reduced LVEF under contemporary optimal medical treatment (OMT) appears imperative.
OBJECTIVE:
To demonstrate that in post-MI patients with symptomatic heart failure who receive OMT for this condition, and with reduced LVEF ≤ 35%, OMT without ICD implantation (index group) is not inferior to OMT with ICD implantation (control group) with respect to all-cause mortality.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion criterion I3 defines myocardial infarction according to the 2018 ESC/ACC/AHA/WHF Fourth Universal Definition of myocardial infarction
Exclusion Criteria:
On the waiting list for heart transplantation.
Class I or IIa indication for implantation of an ICD for secondary prevention of SCD and ventricular tachy-cardia has to be assessed according to the 2022 ESC Guidelines for the management of patients with ven-tricular arrhythmias and the prevention of SCD.
Parallel participation in sub-studies connected to this trial is permitted as well as in purely observational studies without any pre-defined intervention.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure / chronic coronary syndromes and will receive an ICD device
Device: Implantable cardioverter-defibrillator (ICD) · Drug: Optimal Medical Therapy (OMT)
Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure / chronic coronary syndromes and will not receive an ICD device
Drug: Optimal Medical Therapy (OMT)
A transvenous ICD consists of an electronic medical device and electrode leads. Besides the possibility to shock during arrhythmias the ICD can potentially terminate ventricular tachycardias by rapid pacing for short periods (small bursts of pacing). The subcutaneous defibrillator is an established and valid alternative to the transvenous ICD for the prevention of SCD, but in patients without an indication for bradycardia support, cardiac resynchronisation or antitachycardia pacing. The extravascular implantable cardioverter-defibrillator (EV ICD) system with substernal lead placement is a novel nontransvenous alternative to current available transvenous and subcutaneous ICDs.
Patients will be treated according to Optimal Medical Therapy defined by the following guidelines: 1. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes 2. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
Time from randomisation to the occurrence of all-cause death.
Randomization to end of study
Time frame: event-driven, expected about 15 months after last patient in
Time from randomisation to death from cardiovascular causes
Time from randomisation to death from cardiovascular causes
Time frame: Randomization to end of study (event-driven, expected about 15 months after last patient in
Time from randomisation to sudden cardiac death
Time from randomisation to sudden cardiac death
Time frame: Randomization to end of study (event-driven, expected about 15 months after last patient in
Time from randomisation to first hospital readmissions for cardiovascular causes after date of randomisation
Time from randomisation to first hospital readmissions for cardiovascular causes after date of randomisation
Time frame: Randomization to end of study (event-driven, expected about 15 months after last patient in
Average length of stay in hospital during the study period
Average length of stay in hospital during the study period
Time frame: Randomization to end of study (event-driven, expected about 15 months after last patient in
Quality of life (EQ-5D-5L) trajectories over time
Quality of life (EQ-5D-5L) trajectories over time
Time frame: At baseline and 12-month intervals thereafter
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: Undecided
Started Nov 2023 (actual). Primary completion is estimated for Nov 2027, 48 months after the start.
Of 47 non-industry interventional studies with no phase under Death, Sudden, Cardiac, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 86. This study's planned 48 months is above that.
Counting every sponsor, half of 56 studies reached it within 42 months; a quarter within 17 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Charite University, Berlin, Germany →